This site is intended for healthcare professionals
Drug news

FDA accepts sBLA for Dupixent as an add-on maintenance treatment for children with moderate-to-severe atopic dermatitis. Sanofi + Regeneron

Read time: 1 mins
Last updated:29th Jan 2020
Published:29th Jan 2020
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest